[go: up one dir, main page]

CN104884456A - PI3K和/或mTOR抑制剂 - Google Patents

PI3K和/或mTOR抑制剂 Download PDF

Info

Publication number
CN104884456A
CN104884456A CN201380047494.2A CN201380047494A CN104884456A CN 104884456 A CN104884456 A CN 104884456A CN 201380047494 A CN201380047494 A CN 201380047494A CN 104884456 A CN104884456 A CN 104884456A
Authority
CN
China
Prior art keywords
yuan
hydroxyl
optionally
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380047494.2A
Other languages
English (en)
Other versions
CN104884456B (zh
Inventor
吴永谦
舒楚天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xuanzhu Pharma Co Ltd
Original Assignee
Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuanzhu Pharma Co Ltd filed Critical Xuanzhu Pharma Co Ltd
Priority to CN201380047494.2A priority Critical patent/CN104884456B/zh
Publication of CN104884456A publication Critical patent/CN104884456A/zh
Application granted granted Critical
Publication of CN104884456B publication Critical patent/CN104884456B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

提供一类通式(I)化合物、其药学上可接受的盐、立体异构体和溶剂化物，以及其制备方法和含有通式(I)化合物的药物组合物。还提供这些化合物制备治疗和/或预防增殖性疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380047494.2A 2012-09-12 2013-09-12 PI3K和/或mTOR抑制剂 Active CN104884456B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380047494.2A CN104884456B (zh) 2012-09-12 2013-09-12 PI3K和/或mTOR抑制剂

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201210334795 2012-09-12
CN2012103347950 2012-09-12
CN201380047494.2A CN104884456B (zh) 2012-09-12 2013-09-12 PI3K和/或mTOR抑制剂
PCT/CN2013/001061 WO2014040373A1 (zh) 2012-09-12 2013-09-12 PI3K和/或mTOR抑制剂

Publications (2)

Publication Number Publication Date
CN104884456A true CN104884456A (zh) 2015-09-02
CN104884456B CN104884456B (zh) 2017-08-11

Family

ID=50277539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380047494.2A Active CN104884456B (zh) 2012-09-12 2013-09-12 PI3K和/或mTOR抑制剂

Country Status (6)

Country Link
US (1) US9365572B2 (zh)
EP (1) EP2896622B1 (zh)
JP (1) JP6073480B2 (zh)
CN (1) CN104884456B (zh)
HK (1) HK1210464A1 (zh)
WO (1) WO2014040373A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024255837A1 (zh) * 2023-06-15 2024-12-19 石药集团中奇制药技术（石家庄）有限公司 一种enpp1抑制剂的晶型

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109909A1 (zh) * 2021-12-15 2023-06-22 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256966A (zh) * 2008-10-17 2011-11-23 白头生物医学研究所 可溶性mTOR复合物和其调节剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN102399220A (zh) * 2010-09-15 2012-04-04 黄振华 三并环类PI3K和mTOR双重抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109599A1 (en) * 2007-03-05 2008-09-12 Wyeth Pyrimido [5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof
JP5820080B2 (ja) 2011-11-17 2015-11-24 山▲東▼▲軒▼竹医▲葯▼科技有限公司 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256966A (zh) * 2008-10-17 2011-11-23 白头生物医学研究所 可溶性mTOR复合物和其调节剂
CN102399220A (zh) * 2010-09-15 2012-04-04 黄振华 三并环类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024255837A1 (zh) * 2023-06-15 2024-12-19 石药集团中奇制药技术（石家庄）有限公司 一种enpp1抑制剂的晶型

Also Published As

Publication number Publication date
HK1210464A1 (zh) 2016-04-22
EP2896622A1 (en) 2015-07-22
WO2014040373A1 (zh) 2014-03-20
JP2015531779A (ja) 2015-11-05
CN104884456B (zh) 2017-08-11
EP2896622B1 (en) 2017-05-03
US20150239885A1 (en) 2015-08-27
JP6073480B2 (ja) 2017-02-01
EP2896622A4 (en) 2016-03-16
US9365572B2 (en) 2016-06-14

Similar Documents

Publication Publication Date Title
JP7079303B2 (ja) Ｒｅｔキナーゼ阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
EP4328225A1 (en) Heterocyclic derivative inhibitor and preparation method therefor and application thereof
JP6785819B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
CA2785749C (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
CN105085489B (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
EP2931722B1 (en) Substituted 1h-pyrrolo [2,3-b]pyridine and 1h-pyrazolo [3, 4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors
CN102399233B (zh) PI3K和mTOR双重抑制剂类化合物
CN106459068B (zh) 新组合物、用途和制备它们的方法
CN105461714B (zh) 并环类pi3k抑制剂
EP2995618B1 (en) [1,2,4]triazol [4,3-a]pyridine derivate, preparation method therefor or medical application thereof
CN103224496B (zh) 三环类PI3K和/或mTOR抑制剂
TW201245161A (en) 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
KR20090071612A (ko) 단백질 키나제 조정제로서의 바이시클릭 트리아졸
CN105777756A (zh) 杂芳化合物及其在药物中的应用
CN106810536A (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CA2698753A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
EP3865488A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
TW202116753A (zh) 以噌啉作為hpk1的抑制劑
CN104703599A (zh) 作为蛋白激酶抑制剂的氨基异喹啉衍生物
Yan et al. Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
CN114195771B (zh) 多激酶抑制剂及其用途
CN114644627A (zh) AhR抑制剂及其用途
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
CN117105936B (zh) 一种作为FLT3抑制剂的咪唑并[1,2－a]吡啶化合物及其制备方法和用途
CN104884456B (zh) PI3K和/或mTOR抑制剂

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210464

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1210464

Country of ref document: HK